Cornercap Investment Counsel Inc. Purchases Shares of 22,209 Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Cornercap Investment Counsel Inc. purchased a new position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 22,209 shares of the company’s stock, valued at approximately $191,000.

Several other hedge funds and other institutional investors have also made changes to their positions in MLYS. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Mineralys Therapeutics in the fourth quarter worth about $41,000. SG Americas Securities LLC purchased a new stake in shares of Mineralys Therapeutics during the 4th quarter worth approximately $87,000. Vanguard Group Inc. boosted its position in shares of Mineralys Therapeutics by 1.3% during the 3rd quarter. Vanguard Group Inc. now owns 937,638 shares of the company’s stock valued at $8,917,000 after acquiring an additional 11,629 shares during the last quarter. Walleye Capital LLC purchased a new position in shares of Mineralys Therapeutics in the third quarter valued at $145,000. Finally, Sectoral Asset Management Inc. increased its position in Mineralys Therapeutics by 36.8% in the third quarter. Sectoral Asset Management Inc. now owns 840,759 shares of the company’s stock worth $7,996,000 after purchasing an additional 226,046 shares during the last quarter. Institutional investors own 84.46% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. The Goldman Sachs Group assumed coverage on shares of Mineralys Therapeutics in a research report on Tuesday, April 2nd. They set a “buy” rating and a $30.00 price objective for the company. Lifesci Capital reaffirmed an “outperform” rating on shares of Mineralys Therapeutics in a report on Tuesday, March 26th.

Insiders Place Their Bets

In other Mineralys Therapeutics news, major shareholder Samsara Biocapital Gp, Llc bought 555,555 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were purchased at an average price of $13.50 per share, with a total value of $7,499,992.50. Following the completion of the purchase, the insider now owns 5,074,916 shares in the company, valued at approximately $68,511,366. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Mineralys Therapeutics Stock Performance

Shares of MLYS opened at $12.00 on Thursday. The business has a fifty day moving average of $13.78 and a 200 day moving average of $10.31. Mineralys Therapeutics, Inc. has a 52-week low of $5.85 and a 52-week high of $17.70.

Mineralys Therapeutics (NASDAQ:MLYS) last released its earnings results on Thursday, March 21st. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.24. As a group, equities research analysts forecast that Mineralys Therapeutics, Inc. will post -2.44 EPS for the current fiscal year.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.